Tanvex BioPharma Inc 2023 Annual Report with Sustainability Disclosures
Company: Tanvex BioPharma Inc
Sector: Manufacturing
Country: Taiwan
Year: 2023
Type: Annual Report with Sustainability Disclosures
Pages: 203
The report describes the company's strongest performance since listing, with 2023 operating revenue of NT$61,411 thousand and approximately 174% growth driven largely by CDMO work. Tanvex expanded its CDMO capabilities across Taiwan and the United States while continuing investment in biosimilar and new-drug development. TX01 received Canadian licensing and a Canadian distribution agreement with Sandoz, while its U.S. BLA review continued. The company also reported 186 employees at year-end 2023.
Services
From bulk PDFs to structured indicators and machine-readable documents.